Lutetium-177 PSMA therapy (Lu-177 PSMA) is a breakthrough in the treatment of advanced prostate cancer. This targeted radioligand therapy uses a radioactive isotope (Lutetium-177) attached to a molecule that binds specifically to PSMA (Prostate-Specific Membrane Antigen)—a protein found in high levels on prostate cancer cells. At Neolife Medical Center, we provide internationally recognized Lu-177 PSMA treatment using advanced nuclear medicine technology and personalized care for patients around the world.
Lutetium PSMA treatment is primarily recommended for men with metastatic castration-resistant prostate cancer (mCRPC)—a stage of prostate cancer that has spread to other parts of the body and no longer responds to hormonal therapy.
You may be a candidate for Lu-177 PSMA therapy if:
At Neolife Medical Center, we are proud to be one of the few centers in the region offering Lutetium-177 PSMA therapy in a highly controlled and professional setting. Our center is equipped with cutting-edge nuclear medicine technology and supported by a multidisciplinary team focused on your comfort and outcome.
Here’s what makes Neolife a preferred destination for this advanced therapy:
At Neolife, we combine medical precision with compassionate care—making your journey toward better health as effective and comfortable as possible.
Accessing Lu-177 PSMA therapy at Neolife Medical Center is straightforward and supported at every step by our International Patient Department. Here’s how you can begin:
Explore Advanced Prostate Cancer Care with Neolife
Contact Neolife Medical Center today to learn how Lutetium PSMA Treatment can help you or your loved one live better and longer.